LENZ Therapeutics (LENZ) Scheduled to Post Quarterly Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) will announce its earnings results before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.09. On average, analysts expect LENZ Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

LENZ Therapeutics Stock Performance

Shares of LENZ stock opened at $27.93 on Monday. LENZ Therapeutics has a 12-month low of $14.07 and a 12-month high of $31.00. The company has a 50 day moving average of $24.03 and a 200-day moving average of $20.74.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on LENZ. Piper Sandler reissued an “overweight” rating and issued a $36.00 price target on shares of LENZ Therapeutics in a research report on Thursday, August 15th. William Blair upgraded LENZ Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Raymond James began coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They set an “outperform” rating and a $37.00 price objective for the company. Finally, HC Wainwright assumed coverage on shares of LENZ Therapeutics in a report on Monday, August 12th. They issued a “buy” rating and a $38.00 price target for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $35.40.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.